Back to search

Article

Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort Study

2022-09-12

Abstract excerpt

Background: Due to immunity waning over time and emergence of the Omicron variant, a third dose is recommended after two doses of mRNA COVID-19 vaccine. However, there are limited data regarding the efficacy of a third vaccination in solid tumour patients who received a primary series of two ChAdOx1 vaccines.<br><br>Methods: Solid cancer patients who received two ChAdOx1 vaccines were boosted with a third mRNA COV...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1e63a679-5691-53f8-b702-cad1e639b0dd
DOI
10.2139/ssrn.4216696
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and Omicron Neutralization Following a Third COVID-19 Vaccination in Solid Cancer Patients Previously Primed with Two Doses of Chadox1 Vaccine: A Prospective Cohort StudyDOI 10.2139/ssrn.4216696
Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity
Real-World Data on Neutralizing Antibody and Safety of COVID-19 Vaccine against SAR-CoV2 Wild Type and Omicron Variant in Solid Cancer PatientsSemantic proximity
COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with CancerSemantic proximity
Longitudinal Vaccine-Induced Humoral Immune Response in Cancer PatientsSemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudySemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Cancer Patients: Completed Prospective Observational Study Using BNT162b2 mRNA VaccineSemantic proximity
Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)Semantic proximity
Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA VaccinesSemantic proximity
Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.